Merck's Tredaptive pulled after failed study; Medtronic snags infusion pump patent;

> Merck ($MRK) pulled its cholesterol drug Tredaptive (extended-release niacin and laropiprant combination) from the market after failures in the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study. Story

> Molecular handshake could lead to new ways to deliver insulin. Article

> Medtronic ($MDT) acquired a patent for an infusion pump combined with a cardiovascular agent designed for delivery into the central nervous system to improve cardiac performance. Release

> Catalent Pharma Solutions is set to invest $20 million to upgrade its Inhalation Center of Excellence in Research Triangle Park, NC, to expand its development of inhaled drugs. Release

> Researchers at China's Fudan University have developed a method for increasing the stability and absorption of siRNA (small interfering RNA) by encapsulating it using nanoparticles. Release

> The FDA said it would require lower controlled-release doses of popular sleep medications containing zolpidem after data showed that people--women, in particular--who took the drugs in the evening exhibited impaired driving in the morning. Release

> Public-private consortium COMPACT and researchers and educators in the U.K.'s Innovative Medicines Initiative and University of Oxford have launched a €30 million project to further the field of biopharmaceutical drug delivery. Article

> GlaxoSmithKline ($GSK) and Theravance ($THRX) have submitted an application in Europe and the U.S. for the once-daily UMEC/VI for treatment of chronic obstructive pulmonary disease. Release

> Pluristem Therapeutics ($PSTI) gained approval from the Paul-Ehrlich-Institute in Germany for a Phase II study using PLX-PAD cells in patients with intermittent claudication. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.